The neutralizing antibodies against TCRγ/δ, TCR Vγ4, TCR Vγ1 or isotype control were i.p. injected, as shown in Figure 7A. After anti-TCRγ/δ mAb treatment at 1 day before infection, 92.9% of γδT cells in the lungs were depleted on the day of infection (the percentage of γδT cells in the lungs was decreased from 0.57% in the PBS-treated control group to 0.04%), and the depletion lasted until 7 dpi (Figure 7B). Here, TRGC1 is linked to infection.